Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: Natural killer cell mediated cytotoxicity (mmu04650)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
14927508
3
KLA  ATP  ATP+KLA
 149275083 Unknown KLA .74 .68 .68 .77 .71 .85 .69
ATP .85 .69 1.26 .89 .89 1.26 .64
KLA/ATP .64 .63 1.07 .96 1.39 1.07 .82
1500003O
03Rik
KLA  ATP  ATP+KLA
 NM_019769 RIKEN cDNA 1500003O03 gene (1500003O03Rik), mRNA [NM_019769] KLA .92 .89 .89 .86 .85 .92 1.08
ATP 1.01 1.16 1.16 1.53 1.70 3.33 2.09
KLA/ATP .89 .97 .93 1.17 1.19 2.86 2.57
2010110P
09Rik
KLA  ATP  ATP+KLA
 NM_027363 RIKEN cDNA 2010110P09 gene (2010110P09Rik), mRNA [NM_027363] KLA .99 .98 1.02 .99 .94 1.01 1.01
ATP 1.04 1.05 .97 1.05 .95 .98 .95
KLA/ATP .93 1.00 1.02 .97 1.01 .96 .97
AK036998
KLA  ATP  ATP+KLA
 AK036998 adult female vagina cDNA, RIKEN full-length enriched library, clone:9930034M05 product:unclassifiable, full insert sequence. [AK036998] KLA 1.43 1.09 .89 .79 .96 .97 .71
ATP 1.04 1.04 .71 .64 .90 .82 .82
KLA/ATP 1.34 1.23 1.01 .89 1.10 .82 .75
Araf
KLA  ATP  ATP+KLA
 NM_009703 v-raf murine sarcoma 3611 viral oncogene homolog (Araf), mRNA [NM_009703] KLA .87 .80 .89 .93 1.10 1.19 1.16
ATP 1.09 1.11 1.19 1.18 .78 .53 1.18
KLA/ATP 1.00 .95 .99 .93 .63 .55 1.27
BB113440
KLA  ATP  ATP+KLA
 BB113440 gb|BB113440 RIKEN full-length enriched, adult male urinary bladder Mus musculus cDNA clone 9530041B19 3. [BB113440] KLA .94 .95 .94 .95 1.05 .99 1.05
ATP 1.03 1.07 1.79 1.71 1.51 1.12 1.06
KLA/ATP .95 1.11 1.27 1.15 1.05 1.14 1.25
Bid
KLA  ATP  ATP+KLA
 NM_007544 BH3 interacting domain death agonist (Bid), mRNA [NM_007544] KLA 1.03 1.08 1.09 1.14 1.01 .99 .68
ATP 1.06 1.11 .97 .89 1.04 1.17 1.08
KLA/ATP .88 1.09 .92 1.06 1.16 1.28 1.56
Braf
KLA  ATP  ATP+KLA
 NM_139294 Braf transforming gene (Braf), mRNA [NM_139294] KLA 1.52 1.57 1.55 1.33 1.83 1.52 1.60
ATP 1.08 1.17 1.02 1.37 .95 1.15 .95
KLA/ATP 1.64 1.69 1.39 1.51 1.04 1.31 1.26
Casp3
KLA  ATP  ATP+KLA
 NM_009810 caspase 3 (Casp3), mRNA [NM_009810] KLA 1.66 1.94 2.47 2.61 3.01 2.96 1.44
ATP .90 .99 1.17 1.30 1.01 1.17 .86
KLA/ATP 1.55 1.87 2.40 2.35 2.27 2.84 2.52
Casp3
KLA  ATP  ATP+KLA
 U49929 ICE-like cysteine protease (Lice) mRNA, complete cds. [U49929] KLA 1.71 1.87 2.69 3.11 3.64 3.42 1.52
ATP 1.04 1.07 1.16 1.34 .98 1.27 .86
KLA/ATP 1.80 1.96 2.46 2.91 2.50 3.24 3.10
Cd244
KLA  ATP  ATP+KLA
 NM_018729 CD244 natural killer cell receptor 2B4 (Cd244), mRNA [NM_018729] KLA 1.60 1.65 1.58 1.85 2.65 3.51 1.88
ATP .92 .93 1.03 .89 1.70 2.99 3.26
KLA/ATP 1.39 1.47 1.52 1.23 1.76 3.72 2.91
Cd247
KLA  ATP  ATP+KLA
 AK016078 adult male testis cDNA, RIKEN full-length enriched library, clone:4930549J05 product:unclassifiable, full insert sequence. [AK016078] KLA .95 1.01 .98 1.08 1.01 .95 .99
ATP 1.01 1.05 1.02 .99 1.02 1.01 1.07
KLA/ATP .97 .99 1.00 1.05 1.01 .96 .98
Cd247
KLA  ATP  ATP+KLA
 NM_001113391 CD247 antigen (Cd247), transcript variant zeta, mRNA [NM_001113391] KLA 3.06 3.63 3.61 2.90 3.04 1.93 1.28
ATP 1.07 1.03 1.19 1.21 1.39 1.42 1.12
KLA/ATP 3.09 3.74 2.98 2.90 2.14 2.13 2.41
Cd247
KLA  ATP  ATP+KLA
 NM_031162 CD247 antigen (Cd247), transcript variant eta, mRNA [NM_031162] KLA 1.29 1.35 1.39 1.26 1.35 1.16 1.17
ATP .99 1.01 1.04 1.03 1.08 1.05 1.02
KLA/ATP 1.34 1.42 1.24 1.33 1.18 1.18 1.23
Cd48
KLA  ATP  ATP+KLA
 NM_007649 CD48 antigen (Cd48), mRNA [NM_007649] KLA 1.35 1.36 1.64 1.57 1.80 1.74 1.59
ATP 1.16 1.09 1.13 1.12 .93 .49 1.24
KLA/ATP 1.49 1.50 1.72 1.57 1.55 1.04 1.52
Csf2
KLA  ATP  ATP+KLA
 NM_009969 colony stimulating factor 2 (granulocyte-macrophage) (Csf2), mRNA [NM_009969] KLA 1.44 1.53 1.38 1.37 1.15 1.21 1.14
ATP 1.01 1.02 1.85 9.73 2.64 1.90 1.14
KLA/ATP 1.49 1.84 2.14 2.80 1.67 1.36 1.35
EG629860
KLA  ATP  ATP+KLA
 M17953 gb|Mouse Ig rearranged H-chain V-region mRNA VJ1 [M17953] KLA .96 1.05 1.03 1.08 1.08 1.02 .98
ATP .97 .99 1.05 1.10 .95 .94 .91
KLA/ATP .96 .94 .97 1.04 .97 1.01 .89
Fas
KLA  ATP  ATP+KLA
 AK086933 0 day neonate lung cDNA, RIKEN full-length enriched library, clone:E030012O08 product:tumor necrosis factor receptor superfamily, member 6, full insert sequence. [AK086933] KLA 6.31 6.56 6.33 6.70 4.93 3.74 2.48
ATP .95 1.04 1.33 1.55 1.85 6.00 2.77
KLA/ATP 5.67 7.16 7.71 7.73 6.02 5.79 7.85
Fas
KLA  ATP  ATP+KLA
 NM_007987 Fas (TNF receptor superfamily member 6) (Fas), mRNA [NM_007987] KLA 17.08 17.45 19.08 17.38 13.33 6.78 4.46
ATP .98 .96 1.64 3.05 5.58 12.91 1.89
KLA/ATP 16.57 17.25 26.06 23.57 22.03 16.74 13.29
Fasl
KLA  ATP  ATP+KLA
 NM_010177 Fas ligand (TNF superfamily, member 6) (Fasl), mRNA [NM_010177] KLA 1.03 1.01 1.03 1.02 1.01 1.01 1.00
ATP 1.00 .99 1.04 1.21 1.18 1.20 1.01
KLA/ATP 1.00 1.02 1.07 1.16 1.18 1.23 1.00
Fcer1g
KLA  ATP  ATP+KLA
 J05020 gb|Mouse mast cell high affinity IgE receptor (Fc-epsilon-RI) gamma subunit mRNA, complete cds. [J05020] KLA 1.41 1.43 1.53 1.61 1.91 2.07 2.49
ATP 1.13 1.21 .88 1.25 1.06 .92 1.45
KLA/ATP 1.64 1.64 1.25 1.84 1.45 1.39 2.32
Fcer1g
KLA  ATP  ATP+KLA
 NM_010185 Fc receptor, IgE, high affinity I, gamma polypeptide (Fcer1g), mRNA [NM_010185] KLA 1.49 1.54 1.48 1.62 2.18 2.06 2.35
ATP 1.10 1.16 .78 1.00 .90 .98 1.18
KLA/ATP 1.48 1.67 1.26 1.71 1.33 1.40 2.13
Fcgr4
KLA  ATP  ATP+KLA
 NM_144559 Fc receptor, IgG, low affinity IV (Fcgr4), mRNA [NM_144559] KLA 9.03 8.68 9.82 11.51 11.12 13.01 7.95
ATP 1.04 .95 1.22 1.43 1.17 2.80 4.48
KLA/ATP 8.63 8.84 11.99 11.84 12.40 13.56 12.31
Fyn
KLA  ATP  ATP+KLA
 U70324 Fyn(T) (L-fyn(T)) mRNA, complete cds. [U70324] KLA 1.23 1.27 1.31 1.27 1.31 .87 .48
ATP .88 .71 .66 .75 .90 1.28 .51
KLA/ATP 1.12 1.01 .94 .84 1.25 1.51 .53
Grb2
KLA  ATP  ATP+KLA
 NM_008163 growth factor receptor bound protein 2 (Grb2), mRNA [NM_008163] KLA .92 .88 .90 1.27 1.43 1.22 1.00
ATP 1.02 .83 .51 .42 .92 .70 .57
KLA/ATP .84 .77 .61 .56 1.56 1.49 .52
Grb2
KLA  ATP  ATP+KLA
 U07617 Grb2 adaptor protein (grb2) mRNA, complete cds. [U07617] KLA .83 .80 .95 1.13 1.38 1.36 1.06
ATP .84 .74 .51 .41 .82 .74 .59
KLA/ATP .77 .70 .57 .54 1.49 1.39 .53
Gzmb
KLA  ATP  ATP+KLA
 NM_013542 granzyme B (Gzmb), mRNA [NM_013542] KLA 1.03 .96 1.07 1.10 1.04 .98 1.07
ATP .90 1.05 1.02 .98 .90 1.09 1.02
KLA/ATP .96 .98 1.20 1.17 1.03 1.06 1.07
H2-Bl
KLA  ATP  ATP+KLA
 NM_008199 histocompatibility 2, blastocyst (H2-Bl), mRNA [NM_008199] KLA 1.29 1.32 1.40 1.28 1.36 1.46 1.80
ATP 1.04 1.11 1.02 1.34 1.28 1.32 1.47
KLA/ATP 1.32 1.39 1.34 1.77 1.41 1.61 2.39
H2-D1
KLA  ATP  ATP+KLA
 AK169750 2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, clone:E430019E13 product:histocompatibility 2, D region locus 1, full insert sequence [AK169750] KLA .99 .98 .96 .99 .93 .91 .94
ATP .96 1.01 1.02 .95 1.05 1.00 .98
KLA/ATP .92 .94 .97 .97 .98 .92 1.03
H2-D1
KLA  ATP  ATP+KLA
 NM_010380 histocompatibility 2, D region locus 1 (H2-D1), mRNA [NM_010380] KLA 1.38 1.45 1.73 1.42 1.70 1.76 2.56
ATP 1.15 1.11 .86 1.12 1.19 1.28 1.90
KLA/ATP 1.58 1.72 1.38 1.56 1.38 1.69 3.21
H2-K1
KLA  ATP  ATP+KLA
 M69070 mRNA, complete cds. [M69070] KLA 1.76 1.66 1.78 1.78 1.87 2.23 2.99
ATP .98 .97 1.19 1.45 1.36 1.68 2.17
KLA/ATP 1.68 1.70 1.87 1.96 1.87 2.13 3.82
H2-K1
KLA  ATP  ATP+KLA
 NM_001001892 histocompatibility 2, K1, K region (H2-K1), transcript variant 1, mRNA [NM_001001892] KLA 1.82 1.66 1.73 1.76 1.87 2.29 3.17
ATP .98 .97 1.13 1.32 1.29 1.57 2.09
KLA/ATP 1.64 1.71 1.77 1.82 1.71 2.12 3.91
H2-M1
KLA  ATP  ATP+KLA
 NM_177636 histocompatibility 2, M region locus 1 (H2-M1), mRNA [NM_177636] KLA .99 1.01 1.02 1.02 .97 1.03 1.04
ATP 1.01 .99 1.03 1.07 .92 1.03 .98
KLA/ATP 1.08 .97 .94 1.04 1.00 1.04 1.02
H2-M10.1
KLA  ATP  ATP+KLA
 NM_013544 histocompatibility 2, M region locus 10.1 (H2-M10.1), mRNA [NM_013544] KLA 1.04 1.00 1.05 .95 .98 1.04 .94
ATP 1.06 1.04 .96 .95 .97 .98 .98
KLA/ATP 1.02 1.07 .98 1.02 .92 .92 .99
H2-M10.2
KLA  ATP  ATP+KLA
 NM_177923 histocompatibility 2, M region locus 10.2 (H2-M10.2), mRNA [NM_177923] KLA 2.18 2.23 2.51 2.61 2.90 3.30 3.40
ATP 1.08 1.02 1.22 1.39 1.30 1.56 2.66
KLA/ATP 2.23 2.53 2.82 2.91 2.89 2.60 3.92
H2-M10.3
KLA  ATP  ATP+KLA
 AY211080 major histocompatibility complex class Ib M10.3 mRNA, complete cds [AY211080] KLA .95 1.08 .99 .95 1.00 1.11 1.04
ATP .98 .96 1.00 .99 1.00 .99 1.00
KLA/ATP 1.00 .99 1.00 1.00 .99 .96 1.03
H2-M10.4
KLA  ATP  ATP+KLA
 NM_177634 histocompatibility 2, M region locus 10.4 (H2-M10.4), mRNA [NM_177634] KLA 1.03 1.04 1.08 1.08 1.04 1.03 1.03
ATP 1.07 1.05 .97 1.08 .95 .97 1.02
KLA/ATP 1.02 .97 1.02 .99 .93 1.06 1.04
H2-M10.5
KLA  ATP  ATP+KLA
 NM_177637 histocompatibility 2, M region locus 10.5 (H2-M10.5), mRNA [NM_177637] KLA 1.00 1.04 1.13 .93 .99 1.00 1.07
ATP 1.02 1.02 1.04 .90 1.03 .99 .99
KLA/ATP 1.06 1.03 .97 1.03 1.03 .98 1.04
H2-M10.6
KLA  ATP  ATP+KLA
 NM_201611 histocompatibility 2, M region locus 10.6 (H2-M10.6), mRNA [NM_201611] KLA 1.06 .99 1.04 1.06 .98 1.03 .92
ATP 1.04 1.09 .96 .98 .94 1.07 .98
KLA/ATP 1.01 1.06 1.02 .96 .96 1.04 1.05
H2-M11
KLA  ATP  ATP+KLA
 NM_177635 histocompatibility 2, M region locus 11 (H2-M11), mRNA [NM_177635] KLA 1.03 1.07 1.06 1.02 .96 1.05 1.03
ATP 1.02 .96 1.08 .98 1.04 .94 .98
KLA/ATP 1.03 1.03 .99 1.01 1.01 .98 .99
H2-M3
KLA  ATP  ATP+KLA
 NM_013819 histocompatibility 2, M region locus 3 (H2-M3), mRNA [NM_013819] KLA 1.90 2.04 2.09 2.37 2.30 2.56 2.73
ATP 1.00 1.00 1.19 1.34 1.00 .70 1.09
KLA/ATP 1.77 1.94 2.37 2.49 1.89 1.67 2.06
H2-M9
KLA  ATP  ATP+KLA
 NM_008205 histocompatibility 2, M region locus 9 (H2-M9), mRNA [NM_008205] KLA 1.03 .99 .96 .98 1.01 .99 1.03
ATP .96 1.06 .94 .96 1.05 1.06 1.00
KLA/ATP .96 1.01 1.01 .99 .97 .95 .98
H2-Q1
KLA  ATP  ATP+KLA
 NM_010390 histocompatibility 2, Q region locus 1 (H2-Q1), mRNA [NM_010390] KLA 1.05 1.08 1.03 1.02 .98 1.09 1.00
ATP .99 .92 .93 1.01 1.01 1.04 1.00
KLA/ATP 1.07 1.00 1.00 .91 .97 1.07 1.04
H2-Q10
KLA  ATP  ATP+KLA
 NM_010391 histocompatibility 2, Q region locus 10 (H2-Q10), mRNA [NM_010391] KLA 1.50 1.50 1.70 1.64 1.67 1.79 2.18
ATP 1.12 1.11 1.09 1.46 1.42 1.43 1.69
KLA/ATP 1.61 1.72 1.79 1.94 1.81 1.81 2.93
H2-Q2
KLA  ATP  ATP+KLA
 NM_010392 histocompatibility 2, Q region locus 2 (H2-Q2), mRNA [NM_010392] KLA 1.55 1.52 1.61 1.45 1.83 1.94 2.47
ATP 1.09 1.13 .92 1.16 1.17 1.30 1.88
KLA/ATP 1.55 1.70 1.58 1.80 1.64 1.87 3.43
H2-Q7
KLA  ATP  ATP+KLA
 NM_010394 histocompatibility 2, Q region locus 7 (H2-Q7), mRNA [NM_010394] KLA 1.57 1.58 1.74 1.55 1.82 2.00 2.76
ATP 1.05 1.09 .84 1.12 1.12 1.23 2.00
KLA/ATP 1.63 1.75 1.43 1.67 1.53 1.80 3.48
H2-Q8
KLA  ATP  ATP+KLA
 NM_023124 histocompatibility 2, Q region locus 8 (H2-Q8), mRNA [NM_023124] KLA 7.48 6.46 6.41 7.15 7.46 9.60 18.27
ATP 1.01 .98 1.48 2.05 1.93 3.83 8.26
KLA/ATP 6.72 7.10 9.11 10.95 10.71 12.88 31.43
H2-T22
KLA  ATP  ATP+KLA
 NM_010397 histocompatibility 2, T region locus 22 (H2-T22), mRNA [NM_010397] KLA 5.21 5.40 5.81 6.31 7.42 9.49 7.50
ATP 1.01 .95 .88 .92 .93 3.65 5.53
KLA/ATP 4.83 5.12 4.58 4.74 4.81 6.89 14.89
H2-T23
KLA  ATP  ATP+KLA
 NM_010398 histocompatibility 2, T region locus 23 (H2-T23), mRNA [NM_010398] KLA 1.83 1.80 1.92 1.86 2.32 2.56 3.43
ATP 1.03 1.08 .85 1.18 1.09 1.30 2.49
KLA/ATP 1.76 1.92 1.62 1.93 1.76 2.13 4.06
H2-T24
KLA  ATP  ATP+KLA
 NM_008207 histocompatibility 2, T region locus 24 (H2-T24), mRNA [NM_008207] KLA 3.02 3.26 4.14 4.26 5.15 6.06 5.89
ATP 1.08 1.09 1.32 1.35 1.17 1.71 6.71
KLA/ATP 3.23 3.31 3.54 3.85 3.07 3.73 9.10
H2-T3
KLA  ATP  ATP+KLA
 NM_008208 histocompatibility 2, T region locus 3 (H2-T3), mRNA [NM_008208] KLA .95 1.04 1.00 .97 .97 .99 1.00
ATP .98 1.08 1.03 1.01 .98 1.02 1.03
KLA/ATP 1.05 .96 1.02 1.04 1.05 1.00 .97
H60a
KLA  ATP  ATP+KLA
 NM_010400 histocompatibility 60a (H60a), mRNA [NM_010400] KLA 1.29 1.34 1.42 1.56 1.49 1.69 1.71
ATP 1.11 1.03 1.15 1.30 1.04 1.01 2.25
KLA/ATP 1.41 1.47 1.49 1.46 1.30 1.09 2.18
Hcst
KLA  ATP  ATP+KLA
 NM_011827 hematopoietic cell signal transducer (Hcst), mRNA [NM_011827] KLA 1.04 1.08 1.17 1.24 1.05 .92 .88
ATP 1.10 1.00 1.17 1.57 1.29 1.08 1.22
KLA/ATP 1.17 1.27 1.33 1.59 1.39 1.03 1.36
Hras1
KLA  ATP  ATP+KLA
 NM_008284 Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] KLA .79 .82 .77 .82 .94 1.03 1.07
ATP 1.01 .95 .69 .83 .79 1.12 1.15
KLA/ATP .84 .77 .61 .65 .82 1.00 1.05
Icam1
KLA  ATP  ATP+KLA
 BC008626 intercellular adhesion molecule, mRNA (cDNA clone MGC:6195 IMAGE:3588949), complete cds [BC008626] KLA 36.67 32.93 28.63 27.91 14.65 8.16 4.15
ATP .96 .88 1.50 3.88 4.98 3.90 1.01
KLA/ATP 32.58 31.60 42.74 32.60 26.00 13.02 6.01
Icam1
KLA  ATP  ATP+KLA
 NM_010493 intercellular adhesion molecule 1 (Icam1), mRNA [NM_010493] KLA 15.66 15.20 12.96 12.31 9.39 6.17 3.81
ATP .96 1.06 1.21 4.19 4.33 3.16 1.06
KLA/ATP 14.31 15.46 17.84 17.60 13.77 8.36 5.42
Icam2
KLA  ATP  ATP+KLA
 NM_010494 intercellular adhesion molecule 2 (Icam2), mRNA [NM_010494] KLA .90 .84 .82 .72 .67 .61 .70
ATP 1.08 .96 1.28 1.48 2.29 1.22 .62
KLA/ATP .89 .89 1.11 1.00 1.32 1.23 .87
Ifna12
KLA  ATP  ATP+KLA
 NM_177361 interferon alpha 12 (Ifna12), mRNA [NM_177361] KLA 1.25 1.26 1.34 1.16 1.06 1.10 1.09
ATP 1.01 .97 1.07 1.09 1.17 1.20 1.07
KLA/ATP 1.12 1.29 1.72 1.54 1.59 1.56 1.05
Ifna13
KLA  ATP  ATP+KLA
 NM_177347 interferon alpha 13 (Ifna13), mRNA [NM_177347] KLA 1.32 1.27 1.26 1.34 1.15 1.24 1.20
ATP .95 1.08 1.29 1.79 1.41 1.22 1.08
KLA/ATP 1.36 1.35 2.04 2.81 2.07 1.44 1.19
Ifna2
KLA  ATP  ATP+KLA
 K01411 gb|Mouse alpha-interferon (MuIFN-alpha), 3 cds & untranslated mRNA [K01411] KLA 1.02 1.03 1.10 .96 .93 .99 1.01
ATP 1.02 .98 1.00 .98 1.02 .97 .95
KLA/ATP 1.02 1.04 1.18 1.08 1.13 1.04 1.01
Ifna2
KLA  ATP  ATP+KLA
 NM_010503 interferon alpha 2 (Ifna2), mRNA [NM_010503] KLA 1.08 1.06 1.07 1.06 .98 1.02 1.05
ATP .94 1.06 1.11 1.30 1.24 1.25 1.21
KLA/ATP 1.03 1.20 1.19 1.35 1.52 1.60 1.18
Ifna4
KLA  ATP  ATP+KLA
 NM_010504 interferon alpha 4 (Ifna4), mRNA [NM_010504] KLA .99 1.04 1.05 .97 1.00 .96 .99
ATP 1.01 .96 .98 1.01 1.00 1.00 .97
KLA/ATP 1.10 1.09 1.05 1.04 1.01 .97 1.01
Ifna5
KLA  ATP  ATP+KLA
 NM_010505 interferon alpha 5 (Ifna5), mRNA [NM_010505] KLA 1.15 1.23 1.51 1.26 1.03 1.06 1.05
ATP .99 .94 1.11 1.00 1.09 1.07 1.03
KLA/ATP 1.12 1.29 1.46 1.47 1.24 1.32 1.03
Ifna9
KLA  ATP  ATP+KLA
 NM_010507 interferon alpha 9 (Ifna9), mRNA [NM_010507] KLA 1.05 1.09 1.20 1.06 1.08 1.06 1.02
ATP .99 1.08 1.18 1.21 1.09 .99 .97
KLA/ATP 1.09 1.23 1.19 1.24 1.18 1.16 1.04
Ifnab
KLA  ATP  ATP+KLA
 BC116864 interferon alpha B, mRNA (cDNA clone MGC:151241 IMAGE:40126183), complete cds [BC116864] KLA 1.20 1.33 1.29 1.30 1.20 1.20 1.08
ATP .99 .99 1.00 1.25 1.13 1.19 1.04
KLA/ATP 1.30 1.39 1.44 1.48 1.49 1.54 1.22
Ifnar1
KLA  ATP  ATP+KLA
 NM_010508 interferon (alpha and beta) receptor 1 (Ifnar1), mRNA [NM_010508] KLA 1.35 1.29 1.19 1.39 1.60 1.47 1.49
ATP 1.18 1.25 .94 1.06 1.07 1.48 1.52
KLA/ATP 1.56 1.57 .98 1.43 1.08 1.79 3.54
Ifnar2
KLA  ATP  ATP+KLA
 NM_010509 interferon (alpha and beta) receptor 2 (Ifnar2), transcript variant 1, mRNA [NM_010509] KLA 1.45 1.43 1.67 1.87 2.31 1.84 1.36
ATP .99 .92 .87 1.03 1.38 1.79 1.43
KLA/ATP 1.48 1.48 1.24 1.54 1.77 2.10 2.81
Ifnb1
KLA  ATP  ATP+KLA
 NM_010510 interferon beta 1, fibroblast (Ifnb1), mRNA [NM_010510] KLA 49.82 46.57 34.05 16.05 5.94 7.31 8.49
ATP .99 1.02 1.89 4.78 6.31 4.44 1.79
KLA/ATP 49.22 61.83 134.08 144.05 110.96 31.78 11.24
Ifng
KLA  ATP  ATP+KLA
 NM_008337 interferon gamma (Ifng), mRNA [NM_008337] KLA 1.05 1.02 1.01 1.01 1.01 1.04 1.00
ATP 1.00 1.01 1.01 .98 .97 1.04 1.03
KLA/ATP 1.01 1.01 1.06 1.10 1.24 1.10 1.04
Ifngr1
KLA  ATP  ATP+KLA
 NM_010511 interferon gamma receptor 1 (Ifngr1), mRNA [NM_010511] KLA .81 .60 .37 .35 .34 .39 .54
ATP 1.05 .96 1.15 .97 .80 .67 .45
KLA/ATP .57 .57 .63 .36 .28 .33 .36
Ifngr2
KLA  ATP  ATP+KLA
 NM_008338 interferon gamma receptor 2 (Ifngr2), mRNA [NM_008338] KLA 1.45 1.49 1.74 2.22 3.22 2.42 1.96
ATP 1.11 1.03 .81 .78 1.12 1.28 1.34
KLA/ATP 1.48 1.41 1.17 1.23 1.48 1.89 2.13
Igh-VJ55
8
KLA  ATP  ATP+KLA
 AY547436 immunoglobulin heavy chain VDJ region mRNA, partial cds [AY547436] KLA 1.06 1.05 1.01 .93 1.03 .96 .93
ATP .99 1.00 1.06 .95 .96 1.06 1.05
KLA/ATP .98 .94 1.07 .95 .97 .99 1.02
Igh-VJ55
8
KLA  ATP  ATP+KLA
 CA578712 gb|K0727F04-5N NIA Mouse Hematopoietic Stem Cell (Lin- [CA578712] KLA .99 .94 1.01 1.10 .93 .97 .92
ATP .93 1.04 1.01 .98 1.05 .96 .95
KLA/ATP .99 .95 .95 .98 1.02 .98 .95
Igh-VJ55
8
KLA  ATP  ATP+KLA
 ENSMUST00000103412 ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE_DB;Acc:IGHA] [ENSMUST00000103412] KLA 1.01 .97 1.20 1.01 .98 1.44 1.24
ATP .99 .98 1.07 1.03 1.00 1.01 1.21
KLA/ATP .99 1.02 .96 1.03 .97 1.13 1.30
Igh-VJ55
8
KLA  ATP  ATP+KLA
 ENSMUST00000103413 ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE_DB;Acc:IGHE] [ENSMUST00000103413] KLA 1.00 .99 1.06 1.06 .99 1.03 1.02
ATP 1.08 1.06 1.06 1.06 1.02 1.06 .95
KLA/ATP 1.00 1.04 1.09 1.02 1.06 1.02 .95
Igh-VJ55
8
KLA  ATP  ATP+KLA
 U39781 J558+ IgM heavy chain mRNA, hybridoma clone ME2B7, partial cds. [U39781] KLA .93 .89 .98 .97 1.03 1.00 .94
ATP 1.04 1.02 1.08 .94 .93 .90 .79
KLA/ATP .88 .89 .97 .93 .88 .92 .82
Itgal
KLA  ATP  ATP+KLA
 AK156251 activated spleen cDNA, RIKEN full-length enriched library, clone:F830013L17 product:integrin alpha L, full insert sequence [AK156251] KLA 5.36 5.78 4.86 5.55 7.02 8.63 11.12
ATP .99 1.17 1.22 1.57 1.35 1.95 3.79
KLA/ATP 5.42 5.89 4.95 5.91 3.96 4.93 10.15
Itgal
KLA  ATP  ATP+KLA
 NM_008400 integrin alpha L (Itgal), mRNA [NM_008400] KLA 4.48 5.17 5.28 5.82 7.82 8.09 16.96
ATP 1.03 1.06 1.24 1.44 1.34 2.02 4.59
KLA/ATP 4.71 5.63 5.49 5.60 3.66 4.65 17.76
Itgb2
KLA  ATP  ATP+KLA
 NM_008404 integrin beta 2 (Itgb2), mRNA [NM_008404] KLA .78 .78 .97 .74 1.04 .94 1.14
ATP 1.24 1.23 .79 .95 1.12 .84 1.10
KLA/ATP .99 1.01 .60 .83 .78 .73 .99
Itgb2l
KLA  ATP  ATP+KLA
 NM_008405 integrin beta 2-like (Itgb2l), mRNA [NM_008405] KLA .87 .98 .98 1.00 1.05 1.07 1.10
ATP 1.24 1.23 1.13 1.14 1.29 1.05 1.05
KLA/ATP 1.02 1.08 1.08 1.06 .98 .93 .95
Kir3dl1
KLA  ATP  ATP+KLA
 NM_177749 killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1 (Kir3dl1), mRNA [NM_177749] KLA 1.01 1.02 .98 1.01 1.03 1.01 1.03
ATP .99 .98 1.05 1.11 .95 1.05 1.04
KLA/ATP .98 1.02 .92 1.10 1.07 .98 1.00
Klra3
KLA  ATP  ATP+KLA
 NM_010648 killer cell lectin-like receptor, subfamily A, member 3 (Klra3), mRNA [NM_010648] KLA 1.02 1.00 .99 .98 .96 1.10 1.41
ATP 1.01 1.01 1.03 1.04 1.00 .94 1.13
KLA/ATP 1.02 1.00 .94 1.02 1.00 1.02 1.02
Klra7
KLA  ATP  ATP+KLA
 NM_014194 killer cell lectin-like receptor, subfamily A, member 7 (Klra7), transcript variant 2, mRNA [NM_014194] KLA 1.03 .96 .99 1.02 1.01 1.03 .99
ATP .99 .95 .95 1.00 1.09 1.05 1.09
KLA/ATP .94 .99 1.01 .99 1.02 1.06 1.08
Klra8
KLA  ATP  ATP+KLA
 NM_010650 killer cell lectin-like receptor, subfamily A, member 8 (Klra8), mRNA [NM_010650] KLA .95 .92 .94 1.02 .97 1.12 1.65
ATP 1.01 .98 1.11 1.05 .99 .99 1.22
KLA/ATP 1.02 1.03 .95 .97 .95 1.01 1.01
Klra9
KLA  ATP  ATP+KLA
 NM_010651 killer cell lectin-like receptor subfamily A, member 9 (Klra9), mRNA [NM_010651] KLA .96 .90 1.01 1.04 .95 1.08 1.68
ATP 1.02 1.05 1.07 1.09 .96 1.04 1.30
KLA/ATP 1.01 .98 1.00 1.03 .94 .99 1.07
Klrb1c
KLA  ATP  ATP+KLA
 NM_008527 killer cell lectin-like receptor subfamily B member 1C (Klrb1c), mRNA [NM_008527] KLA .88 .88 .85 .89 .88 .90 .98
ATP 1.01 .96 1.03 .92 .87 .94 .93
KLA/ATP .87 .93 .86 .89 .87 .87 .85
Klrc1
KLA  ATP  ATP+KLA
 NM_010652 killer cell lectin-like receptor subfamily C, member 1 (Klrc1), mRNA [NM_010652] KLA 1.00 .96 .99 .98 1.00 .98 1.01
ATP 1.03 .97 1.01 .93 1.10 1.03 1.04
KLA/ATP .98 .99 .93 1.08 1.13 .99 1.03
Klrc2
KLA  ATP  ATP+KLA
 AK036555 adult male bone cDNA, RIKEN full-length enriched library, clone:9830133D16 product:killer cell lectin-like receptor subfamily C, member 2, full insert sequence [AK036555] KLA .98 1.00 1.01 1.02 1.09 .95 .95
ATP 1.07 1.04 .96 1.00 1.03 1.21 1.03
KLA/ATP 1.01 1.01 1.08 1.17 1.15 1.13 1.11
Klrc2
KLA  ATP  ATP+KLA
 AK040721 adult male aorta and vein cDNA, RIKEN full-length enriched library, clone:A530020F15 product:killer cell lectin-like receptor subfamily C, member 2, full insert sequence. [AK040721] KLA .93 .97 1.06 .98 .98 .98 1.04
ATP 1.03 1.03 1.01 1.00 1.00 .95 .94
KLA/ATP 1.01 1.07 .99 .96 1.00 .95 .98
Klrc3
KLA  ATP  ATP+KLA
 NM_021378 killer cell lectin-like receptor subfamily C, member 3 (Klrc3), mRNA [NM_021378] KLA .94 .98 1.00 1.05 .98 .99 .97
ATP .98 1.00 .98 1.03 1.07 1.00 .99
KLA/ATP .99 1.02 .98 .99 .95 .97 .98
Klrd1
KLA  ATP  ATP+KLA
 NM_010654 killer cell lectin-like receptor, subfamily D, member 1 (Klrd1), mRNA [NM_010654] KLA .98 .99 .99 .94 .94 .93 1.03
ATP 1.13 1.28 1.48 1.94 1.59 1.04 1.00
KLA/ATP 1.00 .95 1.04 1.20 1.09 1.00 .94
Klrk1
KLA  ATP  ATP+KLA
 NM_033078 killer cell lectin-like receptor subfamily K, member 1 (Klrk1), transcript variant 1, mRNA [NM_033078] KLA 2.39 2.96 3.81 3.16 2.96 1.97 1.34
ATP 1.12 1.05 1.13 1.17 1.06 1.14 1.08
KLA/ATP 2.56 2.79 2.32 2.12 1.68 1.43 1.15
Kras
KLA  ATP  ATP+KLA
 NM_021284 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] KLA .53 .49 .40 .42 .49 .95 1.05
ATP .98 1.01 1.16 1.17 1.39 1.29 1.74
KLA/ATP .50 .47 .50 .56 1.00 1.24 1.58
LOC67670
8
KLA  ATP  ATP+KLA
 XM_992322 ref|PREDICTED: Mus musculus similar to class I (Qa) Q2k antigen (LOC676708), mRNA [XM_992322] KLA 2.18 2.22 2.32 2.27 2.28 2.77 3.62
ATP 1.04 1.17 1.17 2.19 1.83 1.75 2.30
KLA/ATP 2.20 2.44 2.25 3.41 2.30 2.63 5.00
Lat
KLA  ATP  ATP+KLA
 NM_010689 linker for activation of T cells (Lat), mRNA [NM_010689] KLA .91 .95 .94 .87 .76 .63 .48
ATP .97 .99 1.01 1.50 1.59 1.49 1.00
KLA/ATP .91 1.04 .93 1.15 1.11 .96 .65
Lck
KLA  ATP  ATP+KLA
 NM_010693 lymphocyte protein tyrosine kinase (Lck), mRNA [NM_010693] KLA 18.74 17.97 23.64 20.20 17.34 8.29 1.29
ATP 1.00 1.04 1.28 1.30 1.48 2.55 1.44
KLA/ATP 21.76 24.22 23.73 23.04 22.66 12.06 2.90
Lcp2
KLA  ATP  ATP+KLA
 NM_010696 lymphocyte cytosolic protein 2 (Lcp2), mRNA [NM_010696] KLA 9.10 9.37 9.29 7.53 9.33 5.54 4.23
ATP 1.25 1.38 .95 1.73 2.80 2.13 1.06
KLA/ATP 10.47 10.89 6.89 11.38 3.88 1.80 2.82
Map2k1
KLA  ATP  ATP+KLA
 NM_008927 mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] KLA 1.82 2.00 2.31 2.03 2.51 2.20 1.51
ATP .99 1.14 .81 .87 .90 1.57 1.11
KLA/ATP 1.90 2.03 1.50 1.93 1.63 2.03 2.06
Map2k2
KLA  ATP  ATP+KLA
 NM_023138 mitogen-activated protein kinase kinase 2 (Map2k2), mRNA [NM_023138] KLA .96 1.01 1.09 .99 1.11 1.15 1.42
ATP 1.07 1.05 .74 .86 1.04 1.16 1.21
KLA/ATP 1.14 1.03 .68 .78 .85 1.01 1.20
Mapk1
KLA  ATP  ATP+KLA
 NM_001038663 mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] KLA .97 1.03 .93 .86 .79 1.01 1.04
ATP .96 1.18 1.01 1.13 .84 1.04 1.16
KLA/ATP .99 .99 .84 .87 .63 .96 1.26
Mapk1
KLA  ATP  ATP+KLA
 NM_011949 mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] KLA .88 .80 .80 .73 .75 .76 .65
ATP .97 .96 1.06 .88 .90 .68 .48
KLA/ATP .82 .81 .78 .65 .64 .64 .45
Mapk3
KLA  ATP  ATP+KLA
 NM_011952 mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] KLA .81 .85 .88 .72 .79 .73 .90
ATP 1.13 1.30 .92 1.48 1.08 .68 1.03
KLA/ATP 1.01 1.01 .66 1.13 .77 .77 1.16
Mm.19506
1
KLA  ATP  ATP+KLA
 76253707 Unknown KLA 5.35 4.83 5.36 6.20 6.87 9.80 7.83
ATP .97 .90 .96 .77 .80 3.98 5.87
KLA/ATP 4.63 4.51 4.51 3.75 4.39 7.21 16.38
Mm.21312
8
KLA  ATP  ATP+KLA
 141801344 Unknown KLA .96 .95 .83 .77 .52 .99 1.32
ATP .80 .82 1.09 .80 .83 1.19 1.46
KLA/ATP .78 .92 .98 .62 .71 .94 1.41
Mm.22094
6
KLA  ATP  ATP+KLA
 27545180 Unknown KLA 1.00 .93 .97 1.05 1.06 1.29 1.13
ATP .90 .94 1.25 1.18 .85 .62 1.20
KLA/ATP .86 .99 1.14 .99 .83 .70 1.26
Mm.24936
4
KLA  ATP  ATP+KLA
 133892283 Unknown KLA 1.42 1.41 1.61 2.14 2.88 2.49 2.03
ATP .98 .98 .76 .77 1.09 1.23 1.28
KLA/ATP 1.32 1.32 1.07 1.12 1.38 1.85 1.95
Mm.25381
9
KLA  ATP  ATP+KLA
 118130676 Unknown KLA 1.81 1.88 1.96 1.62 1.89 2.44 1.56
ATP .92 .91 1.24 1.01 1.16 2.06 1.95
KLA/ATP 1.62 1.86 1.86 1.41 1.89 2.37 1.97
Mm.33138
9
KLA  ATP  ATP+KLA
 158508469 Unknown KLA .80 .79 .81 .82 .72 .64 .50
ATP .95 .85 .56 .48 .30 .33 .46
KLA/ATP .71 .64 .50 .41 .33 .32 .42
Mm.37708
7
KLA  ATP  ATP+KLA
 158631169 Unknown KLA .98 .98 1.06 1.06 .91 .97 1.04
ATP 1.00 1.07 1.01 1.06 1.09 .99 1.02
KLA/ATP 1.08 1.06 1.16 1.11 1.16 1.12 1.04
Mm.43967
5
KLA  ATP  ATP+KLA
 133778954 Unknown KLA 1.76 1.74 1.70 1.72 1.75 2.14 3.19
ATP 1.00 1.01 1.18 1.28 1.25 1.48 1.84
KLA/ATP 1.67 1.64 1.70 1.79 1.63 2.04 3.36
Mm.43967
5
KLA  ATP  ATP+KLA
 149275074 Unknown KLA 2.17 2.23 2.26 2.58 2.26 2.10 1.43
ATP .96 .91 1.12 .90 .70 1.10 1.47
KLA/ATP 1.96 2.10 1.92 1.51 1.12 1.35 1.99
Mm.43972
4
KLA  ATP  ATP+KLA
 142350027 Unknown KLA 1.01 .96 1.03 .97 1.03 .99 .95
ATP .98 1.02 .96 .96 1.07 .99 .98
KLA/ATP .98 1.03 1.00 1.02 1.00 .99 1.01
Mm.44089
1
KLA  ATP  ATP+KLA
 118130823 Unknown KLA 1.89 1.79 1.51 1.49 1.06 .68 .39
ATP .98 .94 1.11 1.07 .88 .68 .75
KLA/ATP 1.80 1.69 1.89 1.83 1.42 .79 .60
Mm.44165
1
KLA  ATP  ATP+KLA
 160333403 Unknown KLA 5.45 5.27 5.02 6.34 6.63 10.05 8.10
ATP .91 .84 .96 .75 .78 3.91 6.03
KLA/ATP 4.29 4.38 4.50 3.55 4.22 7.22 17.63
Mm.44244
2
KLA  ATP  ATP+KLA
 148747422 Unknown KLA 1.56 1.73 1.94 1.74 1.69 1.53 .87
ATP 1.02 1.11 1.14 1.34 1.32 1.32 1.08
KLA/ATP 1.74 1.94 1.86 1.90 1.69 1.95 2.43
Mm.44463
KLA  ATP  ATP+KLA
 118129851 Unknown KLA 1.01 .98 .97 1.02 .93 1.06 1.05
ATP .97 1.01 1.04 1.06 1.02 1.08 .97
KLA/ATP 1.02 1.06 .95 1.04 1.09 1.14 1.03
Mm.45800
4
KLA  ATP  ATP+KLA
 6679616 Unknown KLA 1.73 1.70 1.47 1.73 1.18 .65 .41
ATP .92 .91 1.06 1.06 1.03 .70 .69
KLA/ATP 1.79 1.66 2.07 1.51 1.37 .95 .70
Mm.57127
KLA  ATP  ATP+KLA
 117168292 Unknown KLA 1.20 1.25 1.28 1.18 1.14 1.13 1.12
ATP .98 .95 1.11 1.06 1.05 1.05 1.09
KLA/ATP 1.22 1.24 1.48 1.55 1.40 1.21 1.07
Ncr1
KLA  ATP  ATP+KLA
 NM_010746 natural cytotoxicity triggering receptor 1 (Ncr1), mRNA [NM_010746] KLA 1.00 .97 .98 .98 1.07 1.06 1.06
ATP 1.01 1.05 .90 1.00 1.04 1.05 .95
KLA/ATP 1.02 .99 .96 1.04 1.04 1.03 1.06
Nfat5
KLA  ATP  ATP+KLA
 AK172011 activated spleen cDNA, RIKEN full-length enriched library, clone:F830029B05 product:nuclear factor of activated T-cells 5, full insert sequence. [AK172011] KLA .94 .90 .93 .93 1.28 1.27 1.16
ATP .95 .76 1.13 1.27 1.93 2.21 1.18
KLA/ATP .85 .84 1.10 .92 1.53 1.63 1.66
Nfat5
KLA  ATP  ATP+KLA
 NM_018823 nuclear factor of activated T-cells 5 (Nfat5), transcript variant b, mRNA [NM_018823] KLA .95 1.01 .99 1.03 1.08 1.13 1.19
ATP 1.05 1.22 1.67 1.98 1.74 1.38 1.17
KLA/ATP 1.03 1.07 1.34 1.38 1.30 1.19 1.40
Nfat5
KLA  ATP  ATP+KLA
 NM_133957 nuclear factor of activated T-cells 5 (Nfat5), transcript variant a, mRNA [NM_133957] KLA 1.07 1.07 1.00 .96 1.42 1.36 1.51
ATP 1.15 1.19 1.81 4.36 6.34 3.49 1.12
KLA/ATP 1.27 1.08 1.87 2.72 3.58 3.05 2.07
Nfatc1
KLA  ATP  ATP+KLA
 NM_016791 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (Nfatc1), transcript variant 1, mRNA [NM_016791] KLA .71 .66 .68 .62 .63 .67 .81
ATP 1.12 1.29 1.15 1.21 .83 .63 1.25
KLA/ATP .78 .79 .65 .74 .59 .45 .92
Nfatc1
KLA  ATP  ATP+KLA
 NM_198429 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (Nfatc1), transcript variant 2, mRNA [NM_198429] KLA .49 .41 .50 .43 .50 .78 .69
ATP 1.05 .81 .84 .54 .60 .38 .69
KLA/ATP .46 .37 .45 .32 .62 .39 .61
Nfatc2
KLA  ATP  ATP+KLA
 AK081853 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130082H17 product:nuclear factor of activated T-cells, cytoplasmic 2, full insert sequence. [AK081853] KLA .56 .52 .59 .61 .78 .78 .66
ATP 1.19 1.27 .67 .65 .62 .53 .79
KLA/ATP .52 .49 .71 .57 .65 .52 .53
Nfatc2
KLA  ATP  ATP+KLA
 NM_001037177 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 (Nfatc2), transcript variant 2, mRNA [NM_001037177] KLA .84 .79 .74 .82 .89 .98 .80
ATP 1.06 1.13 1.01 .87 .86 .83 1.10
KLA/ATP .76 .72 .89 .84 .84 .81 .84
Nfatc2
KLA  ATP  ATP+KLA
 NM_010899 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 (Nfatc2), transcript variant 1, mRNA [NM_010899] KLA .90 .91 .86 .91 .86 1.07 1.00
ATP 1.08 1.11 1.45 1.04 .88 .85 1.18
KLA/ATP .85 .89 .92 .89 .93 .84 1.13
Nfatc3
KLA  ATP  ATP+KLA
 AK084848 13 days embryo lung cDNA, RIKEN full-length enriched library, clone:D430001G08 product:nuclear factor of activated T-cells, cytoplasmic 3, full insert sequence. [AK084848] KLA 1.08 .96 .98 1.00 .98 1.03 .98
ATP 1.00 1.03 .93 .92 .92 1.11 .98
KLA/ATP 1.01 .87 1.10 .97 .96 .96 .99
Nfatc3
KLA  ATP  ATP+KLA
 NM_010901 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 (Nfatc3), mRNA [NM_010901] KLA .77 .68 .67 .77 .85 .90 1.04
ATP 1.01 .95 .89 .70 .70 .92 .98
KLA/ATP .77 .66 .64 .59 .82 .90 .90
Nfatc4
KLA  ATP  ATP+KLA
 AK014164 13 days embryo head cDNA, RIKEN full-length enriched library, clone:3110041H08 product:nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4, full insert sequence. [AK014164] KLA .90 .92 .91 1.00 .99 .98 .95
ATP .90 1.03 .96 .98 .95 .97 1.00
KLA/ATP .95 .87 1.00 .98 .96 .96 .92
Nfatc4
KLA  ATP  ATP+KLA
 NM_023699 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 (Nfatc4), mRNA [NM_023699] KLA 1.28 1.38 1.44 1.58 1.40 1.41 1.46
ATP 1.03 1.06 1.23 1.24 1.32 1.40 1.41
KLA/ATP 1.30 1.38 1.47 1.28 1.38 1.40 1.63
Nras
KLA  ATP  ATP+KLA
 NM_010937 neuroblastoma ras oncogene (Nras), mRNA [NM_010937] KLA 1.20 1.22 1.27 1.20 1.09 .91 .84
ATP .98 .91 .69 .61 .59 .67 .78
KLA/ATP 1.22 1.14 .97 .79 .73 .61 .72
Pak1
KLA  ATP  ATP+KLA
 NM_011035 p21 (CDKN1A)-activated kinase 1 (Pak1), mRNA [NM_011035] KLA .72 .77 .79 .71 .67 .73 .95
ATP 1.10 1.07 .99 1.15 1.27 .62 .51
KLA/ATP .85 .83 .73 .76 .76 .55 .33
Pik3ca
KLA  ATP  ATP+KLA
 ENSMUST00000108243 ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] KLA 1.07 1.01 .91 .90 .98 .96 .86
ATP 1.03 .87 1.12 .63 1.22 1.86 .60
KLA/ATP 1.05 .82 .91 .61 1.17 1.26 .63
Pik3ca
KLA  ATP  ATP+KLA
 NM_008839 phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] KLA 1.15 1.11 1.05 .82 .99 1.03 1.27
ATP .98 1.00 .79 .75 .96 1.32 1.10
KLA/ATP 1.10 .98 .64 .72 .80 1.20 1.41
Pik3cb
KLA  ATP  ATP+KLA
 NM_029094 phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] KLA 1.06 1.06 1.03 .73 .68 .98 1.69
ATP 1.04 1.21 .95 1.02 .85 .93 1.73
KLA/ATP 1.15 1.27 .73 .83 .58 .81 1.81
Pik3cd
KLA  ATP  ATP+KLA
 NM_008840 phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] KLA 2.28 2.42 3.10 4.17 3.35 2.31 1.34
ATP 1.02 .91 .99 .63 .30 .67 .80
KLA/ATP 2.14 2.23 2.70 1.51 1.17 .85 .72
Pik3cd
KLA  ATP  ATP+KLA
 U86587 phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] KLA 2.21 2.24 3.71 3.17 3.67 2.66 1.48
ATP 1.00 1.03 .93 .96 .46 .75 .97
KLA/ATP 2.27 2.32 1.97 2.02 1.01 .99 .98
Pik3cg
KLA  ATP  ATP+KLA
 NM_020272 phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] KLA .53 .53 .61 .64 .97 .86 .79
ATP 1.01 1.13 .88 .89 .52 .53 .53
KLA/ATP .58 .53 .43 .60 .40 .43 .62
Pik3r1
KLA  ATP  ATP+KLA
 NM_001077495 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] KLA 1.05 1.07 1.03 1.00 1.01 1.20 .85
ATP .97 1.02 1.48 1.42 1.76 1.33 1.23
KLA/ATP 1.11 1.12 1.06 1.17 1.24 .99 1.12
Pik3r2
KLA  ATP  ATP+KLA
 NM_008841 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] KLA .50 .50 .48 .43 .46 .66 .75
ATP .78 .68 .45 .43 .28 .57 1.37
KLA/ATP .49 .38 .32 .33 .38 .67 1.10
Pik3r3
KLA  ATP  ATP+KLA
 NM_181585 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] KLA 1.59 1.49 1.37 1.17 1.05 1.55 1.41
ATP 1.12 1.00 1.33 1.70 2.01 2.37 2.02
KLA/ATP 1.63 1.54 1.58 1.70 2.43 2.68 1.92
Pik3r5
KLA  ATP  ATP+KLA
 NM_177320 phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] KLA 3.57 3.58 4.16 3.54 4.11 2.59 2.39
ATP 1.08 1.08 .93 1.67 3.11 1.88 1.34
KLA/ATP 3.91 3.70 3.30 3.80 2.70 2.04 3.00
Plcg2
KLA  ATP  ATP+KLA
 NM_172285 phospholipase C, gamma 2 (Plcg2), mRNA [NM_172285] KLA .76 .74 .68 .66 .71 .92 .95
ATP .96 .90 .95 .87 .81 .79 .91
KLA/ATP .76 .71 .69 .62 .72 .78 .68
Ppp3ca
KLA  ATP  ATP+KLA
 NM_008913 protein phosphatase 3, catalytic subunit, alpha isoform (Ppp3ca), mRNA [NM_008913] KLA .76 .85 .81 .85 .73 .70 .52
ATP .96 .78 .55 .46 .31 .33 .48
KLA/ATP .74 .64 .52 .42 .37 .36 .45
Ppp3cb
KLA  ATP  ATP+KLA
 AK135203 12 days embryo male wolffian duct includes surrounding region cDNA, RIKEN full-length enriched library, clone:6720421K10 product:protein phosphatase 3, catalytic subunit, beta isoform, full insert sequence. [AK135203] KLA 1.74 1.57 1.91 1.59 1.47 1.26 1.40
ATP 1.17 1.03 1.30 1.00 .81 .62 1.37
KLA/ATP 1.68 1.70 1.91 1.37 1.09 .47 1.13
Ppp3cb
KLA  ATP  ATP+KLA
 AK171904 activated spleen cDNA, RIKEN full-length enriched library, clone:F830018L06 product:Protein phosphatase 3 catalytic subunit beta3 (EC 3.1.3.16) (Serine [AK171904] KLA 1.29 1.29 1.21 1.15 1.22 1.13 1.28
ATP .90 .86 .80 .98 .94 .73 .92
KLA/ATP 1.06 1.03 .77 1.04 .92 .68 .90
Ppp3cb
KLA  ATP  ATP+KLA
 NM_008914 protein phosphatase 3, catalytic subunit, beta isoform (Ppp3cb), mRNA [NM_008914] KLA 1.21 1.29 1.38 1.24 1.29 1.08 1.23
ATP 1.15 1.31 1.09 1.29 .86 .60 .64
KLA/ATP 1.33 1.40 1.04 1.28 .79 .58 .73
Ppp3cc
KLA  ATP  ATP+KLA
 AK037563 16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130026K22 product:unclassifiable, full insert sequence [AK037563] KLA 1.27 1.18 1.21 1.15 1.01 .92 1.36
ATP .96 1.09 1.10 1.03 .85 1.06 1.47
KLA/ATP 1.17 1.24 1.07 1.13 .91 .88 1.36
Ppp3cc
KLA  ATP  ATP+KLA
 NM_008915 protein phosphatase 3, catalytic subunit, gamma isoform (Ppp3cc), mRNA [NM_008915] KLA 1.64 1.81 1.79 1.35 .90 .70 1.31
ATP .90 .90 1.13 .93 .86 1.40 1.60
KLA/ATP 1.45 1.62 1.74 1.47 1.04 1.01 1.31
Ppp3r1
KLA  ATP  ATP+KLA
 NM_024459 protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type I) (Ppp3r1), mRNA [NM_024459] KLA 1.02 1.17 .93 1.27 1.15 1.30 1.30
ATP .97 .95 .77 .91 .99 1.18 1.10
KLA/ATP 1.12 1.04 .88 1.00 1.10 1.10 1.07
Ppp3r2
KLA  ATP  ATP+KLA
 NM_001004025 protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type II) (Ppp3r2), mRNA [NM_001004025] KLA 1.03 1.05 1.06 1.08 1.12 1.05 1.04
ATP 1.00 1.02 1.04 1.04 .99 .99 1.01
KLA/ATP 1.04 1.12 1.03 1.09 1.00 .99 1.00
Prf1
KLA  ATP  ATP+KLA
 NM_011073 perforin 1 (pore forming protein) (Prf1), mRNA [NM_011073] KLA .99 1.02 1.05 1.08 1.00 1.03 .98
ATP 1.00 .97 1.03 .97 .97 .98 .91
KLA/ATP 1.07 .99 .93 .98 .98 .95 .99
Prkca
KLA  ATP  ATP+KLA
 NM_011101 protein kinase C, alpha (Prkca), mRNA [NM_011101] KLA 1.00 .96 .94 .95 .95 .89 .96
ATP 1.00 1.03 .91 .94 .82 .87 1.13
KLA/ATP 1.02 .95 .91 .86 .78 .84 .94
Prkcb1
KLA  ATP  ATP+KLA
 NM_008855 protein kinase C, beta 1 (Prkcb1), mRNA [NM_008855] KLA .92 .95 .93 .78 .77 1.08 1.83
ATP 1.03 1.12 1.09 1.23 .90 2.08 .96
KLA/ATP .98 .99 .82 .89 .62 1.01 1.08
Prkcc
KLA  ATP  ATP+KLA
 NM_011102 protein kinase C, gamma (Prkcc), mRNA [NM_011102] KLA 1.02 1.04 1.11 1.04 .96 1.02 1.05
ATP .98 .98 1.05 1.03 1.08 .96 .95
KLA/ATP 1.21 1.16 1.09 1.07 1.04 .98 .93
Ptk2b
KLA  ATP  ATP+KLA
 NM_172498 PTK2 protein tyrosine kinase 2 beta (Ptk2b), mRNA [NM_172498] KLA 1.34 1.39 1.78 1.70 2.36 2.26 1.77
ATP 1.08 1.21 .59 .69 .65 .71 1.17
KLA/ATP 1.41 1.55 1.07 1.33 1.07 1.24 1.80
Ptpn11
KLA  ATP  ATP+KLA
 NM_001109992 protein tyrosine phosphatase, non-receptor type 11 (Ptpn11), transcript variant 2, mRNA [NM_001109992] KLA 1.52 1.71 1.59 1.78 1.62 1.57 1.35
ATP 1.04 .93 .86 .79 1.09 1.95 1.90
KLA/ATP 1.59 1.61 1.45 1.11 1.18 1.82 3.02
Ptpn11
KLA  ATP  ATP+KLA
 NM_011202 protein tyrosine phosphatase, non-receptor type 11 (Ptpn11), transcript variant 1, mRNA [NM_011202] KLA 1.32 1.28 1.17 1.21 1.18 1.06 1.05
ATP .97 .77 .71 .56 .90 1.27 1.04
KLA/ATP 1.22 1.21 1.02 .70 .96 1.06 .94
Ptpn6
KLA  ATP  ATP+KLA
 NM_001077705 protein tyrosine phosphatase, non-receptor type 6 (Ptpn6), transcript variant 2, mRNA [NM_001077705] KLA .87 .90 1.03 1.05 1.83 1.96 2.34
ATP 1.06 1.09 .94 1.08 .51 .34 1.04
KLA/ATP .98 .93 .71 .95 .67 .64 1.44
Ptpn6
KLA  ATP  ATP+KLA
 NM_013545 protein tyrosine phosphatase, non-receptor type 6 (Ptpn6), transcript variant 1, mRNA [NM_013545] KLA 1.24 1.20 1.46 1.42 2.43 2.27 2.10
ATP 1.18 1.20 1.10 1.49 .80 .58 1.09
KLA/ATP 1.36 1.42 1.27 1.66 1.12 .87 1.46
Ptpn6
KLA  ATP  ATP+KLA
 S63763 gb|me/Hcph (mev)=viable motheaten/hematopoietic cell protein-tyrosine phosphatase {insertion} [mice, mRNA Partial Mutant, 120 nt]. [S63763] KLA 1.06 1.03 1.12 1.14 1.11 1.01 1.09
ATP 1.03 .97 .96 .90 .89 1.17 1.76
KLA/ATP 1.07 1.00 1.03 .98 1.00 1.29 1.44
Rac1
KLA  ATP  ATP+KLA
 NM_009007 RAS-related C3 botulinum substrate 1 (Rac1), mRNA [NM_009007] KLA 1.02 1.01 1.02 .99 1.03 1.15 1.08
ATP .99 1.15 1.01 1.27 1.06 1.20 1.06
KLA/ATP 1.00 1.04 .88 1.16 .91 1.21 1.38
Rac2
KLA  ATP  ATP+KLA
 NM_009008 RAS-related C3 botulinum substrate 2 (Rac2), mRNA [NM_009008] KLA 1.55 1.68 1.86 2.15 3.36 3.59 3.74
ATP 1.13 1.16 .74 .99 .84 .91 1.66
KLA/ATP 1.59 1.71 1.19 1.56 1.21 1.60 3.48
Rac3
KLA  ATP  ATP+KLA
 NM_133223 RAS-related C3 botulinum substrate 3 (Rac3), mRNA [NM_133223] KLA 2.03 2.20 2.64 2.18 2.95 2.29 1.41
ATP 1.02 1.12 .94 1.42 1.16 .84 .87
KLA/ATP 2.30 2.32 1.57 2.55 1.75 1.47 1.61
Raet1a
KLA  ATP  ATP+KLA
 NM_009016 retinoic acid early transcript 1, alpha (Raet1a), mRNA [NM_009016] KLA 1.76 1.82 1.73 1.48 1.32 .96 .56
ATP .99 1.02 1.05 1.27 1.00 .77 .91
KLA/ATP 1.76 1.82 1.61 1.90 1.35 .97 1.03
Raet1e
KLA  ATP  ATP+KLA
 NM_198193 retinoic acid early transcript 1E (Raet1e), mRNA [NM_198193] KLA 1.83 1.92 1.73 1.45 1.17 .69 .56
ATP .93 1.00 .97 1.10 .83 .72 1.14
KLA/ATP 1.90 1.72 1.43 1.77 1.16 .78 .80
Raf1
KLA  ATP  ATP+KLA
 AK036317 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] KLA 1.47 1.34 1.55 1.29 1.59 1.32 1.46
ATP 1.05 .98 .54 .63 3.32 2.07 1.01
KLA/ATP 1.57 1.33 .79 .96 2.26 1.38 1.35
Raf1
KLA  ATP  ATP+KLA
 NM_029780 v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] KLA 1.65 1.64 1.93 1.77 1.77 1.72 1.81
ATP .95 .96 .83 .80 2.22 2.92 1.19
KLA/ATP 1.68 1.64 1.39 1.32 1.85 2.50 2.06
Sh2d1a
KLA  ATP  ATP+KLA
 AK042476 3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630095D20 product:SH2 domain protein 1A, full insert sequence. [AK042476] KLA .93 .99 1.01 .99 .98 1.02 1.02
ATP .99 .96 .96 .99 1.08 1.01 .98
KLA/ATP .97 1.07 1.03 1.05 .94 .94 .95
Sh2d1a
KLA  ATP  ATP+KLA
 NM_011364 SH2 domain protein 1A (Sh2d1a), mRNA [NM_011364] KLA 1.04 .97 1.00 1.02 .98 .99 1.00
ATP .95 .98 .97 1.01 .99 1.05 1.03
KLA/ATP .99 1.04 1.01 .97 1.05 .99 1.02
Sh2d1b1
KLA  ATP  ATP+KLA
 AK089191 NOD-derived CD11c +ve dendritic cells cDNA, RIKEN full-length enriched library, clone:F630034C03 product:EWS [AK089191] KLA .87 .82 .81 .83 .78 .88 1.01
ATP 1.06 1.02 .94 .95 .87 .84 .89
KLA/ATP .87 .80 .83 .84 .81 .79 .87
Sh2d1b1
KLA  ATP  ATP+KLA
 NM_012009 SH2 domain protein 1B1 (Sh2d1b1), mRNA [NM_012009] KLA .50 .48 .47 .57 .58 .72 1.19
ATP 1.08 .97 1.04 .90 .66 .75 .79
KLA/ATP .46 .46 .53 .61 .64 1.11 1.48
Sh3bp2
KLA  ATP  ATP+KLA
 NM_011893 SH3-domain binding protein 2 (Sh3bp2), mRNA [NM_011893] KLA 1.07 1.15 1.84 1.48 1.84 1.96 1.57
ATP 1.00 1.12 .78 .45 .76 .88 1.31
KLA/ATP 1.28 1.21 1.18 .83 1.44 1.19 1.89
Shc1
KLA  ATP  ATP+KLA
 NM_011368 src homology 2 domain-containing transforming protein C1 (Shc1), transcript variant 2, mRNA [NM_011368] KLA .88 .87 .86 .83 1.09 1.11 1.12
ATP 1.04 1.25 .85 1.17 .93 1.16 1.00
KLA/ATP .93 .96 .62 .96 .75 1.25 1.19
Shc2
KLA  ATP  ATP+KLA
 NM_001024539 src homology 2 domain-containing transforming protein C2 (Shc2), mRNA [NM_001024539] KLA 1.19 1.25 1.22 1.16 1.15 1.14 .98
ATP 1.04 1.14 1.15 1.53 1.29 1.06 1.09
KLA/ATP 1.26 1.24 1.26 1.49 1.31 1.30 1.30
Shc3
KLA  ATP  ATP+KLA
 NM_009167 src homology 2 domain-containing transforming protein C3 (Shc3), mRNA [NM_009167] KLA 1.00 .98 1.06 1.06 1.12 1.08 1.04
ATP .99 1.02 1.00 1.05 1.00 1.08 1.08
KLA/ATP 1.08 1.06 1.01 1.06 1.03 1.12 1.41
Shc4
KLA  ATP  ATP+KLA
 NM_199022 SHC (Src homology 2 domain containing) family, member 4 (Shc4), mRNA [NM_199022] KLA 1.03 1.03 1.01 1.06 1.09 1.03 1.06
ATP .99 1.00 1.03 1.02 1.04 1.04 1.01
KLA/ATP .98 .97 1.06 1.05 1.00 1.00 1.14
Sos1
KLA  ATP  ATP+KLA
 NM_009231 Son of sevenless homolog 1 (Drosophila) (Sos1), mRNA [NM_009231] KLA 2.36 2.40 3.42 3.15 2.78 1.81 1.71
ATP .99 1.00 .99 1.15 1.14 1.25 1.24
KLA/ATP 2.41 2.26 1.95 2.44 1.47 1.66 1.37
Sos2
KLA  ATP  ATP+KLA
 XM_127051 gb|PREDICTED: Mus musculus Son of sevenless homolog 2 (Drosophila) (Sos2), mRNA [XM_127051] KLA .81 .77 .79 .92 1.04 1.06 1.20
ATP 1.00 1.00 1.09 .79 .68 .81 .94
KLA/ATP .77 .69 .71 .60 .64 .77 1.07
Syk
KLA  ATP  ATP+KLA
 NM_011518 spleen tyrosine kinase (Syk), mRNA [NM_011518] KLA 2.48 2.59 2.57 2.26 3.29 3.75 3.19
ATP .96 .85 .59 1.01 2.80 3.77 2.11
KLA/ATP 2.56 2.09 1.16 1.35 2.50 4.33 5.10
Tnf
KLA  ATP  ATP+KLA
 NM_013693 tumor necrosis factor (Tnf), mRNA [NM_013693] KLA 13.35 12.76 10.71 9.03 10.64 7.39 8.32
ATP 2.01 2.48 8.27 19.20 9.72 4.09 1.49
KLA/ATP 12.72 15.76 12.73 17.34 5.10 3.61 6.07
Tnfrsf10
b
KLA  ATP  ATP+KLA
 NM_020275 tumor necrosis factor receptor superfamily, member 10b (Tnfrsf10b), mRNA [NM_020275] KLA 1.29 1.24 1.23 1.14 .96 .88 .87
ATP .99 1.04 1.06 1.14 .95 1.10 1.15
KLA/ATP 1.26 1.26 1.21 1.23 1.03 .93 .93
Tnfsf10
KLA  ATP  ATP+KLA
 NM_009425 tumor necrosis factor (ligand) superfamily, member 10 (Tnfsf10), mRNA [NM_009425] KLA 31.48 31.73 32.62 36.94 28.34 23.40 4.96
ATP 1.06 .93 1.28 1.24 1.07 2.74 3.33
KLA/ATP 28.07 30.23 43.53 33.98 27.97 18.71 17.43
Tyrobp
KLA  ATP  ATP+KLA
 NM_011662 TYRO protein tyrosine kinase binding protein (Tyrobp), mRNA [NM_011662] KLA .80 .78 .84 .69 .72 .69 .92
ATP 1.10 1.12 .90 1.11 .83 .71 .90
KLA/ATP .92 .90 .64 .87 .65 .61 .92
Ulbp1
KLA  ATP  ATP+KLA
 AK085119 13 days embryo lung cDNA, RIKEN full-length enriched library, clone:D430040B02 product:A430108B07RIK PROTEIN homolog [Mus musculus], full insert sequence [AK085119] KLA 1.71 1.73 1.52 1.01 .69 .76 .42
ATP .97 1.03 1.30 1.02 1.42 1.69 .44
KLA/ATP 1.76 1.93 1.94 1.67 2.09 2.60 1.78
Vav1
KLA  ATP  ATP+KLA
 NM_011691 vav 1 oncogene (Vav1), mRNA [NM_011691] KLA .79 .83 .98 1.17 1.97 2.42 2.26
ATP 1.06 1.02 .88 1.01 1.34 .82 1.36
KLA/ATP .88 .85 .73 .78 1.25 1.47 2.17
Vav2
KLA  ATP  ATP+KLA
 BC053060 vav 2 oncogene, mRNA (cDNA clone MGC:62363 IMAGE:5704852), complete cds [BC053060] KLA .73 .58 .55 1.16 .76 1.35 1.75
ATP .99 .89 .79 .82 .67 .85 1.09
KLA/ATP .64 .63 .61 .65 .66 .80 1.23
Vav2
KLA  ATP  ATP+KLA
 NM_009500 vav 2 oncogene (Vav2), mRNA [NM_009500] KLA .98 1.05 .98 .99 1.02 1.36 1.43
ATP 1.07 1.06 .96 1.01 .89 .95 1.08
KLA/ATP 1.04 1.05 .98 1.03 .88 .99 1.13
Vav3
KLA  ATP  ATP+KLA
 NM_020505 vav 3 oncogene (Vav3), transcript variant 1, mRNA [NM_020505] KLA .95 .94 .86 .87 .82 .66 .56
ATP 1.06 1.09 .81 1.05 .80 .75 .85
KLA/ATP 1.00 .84 .62 .85 .74 .56 .74
Zap70
KLA  ATP  ATP+KLA
 NM_009539 zeta-chain (TCR) associated protein kinase (Zap70), mRNA [NM_009539] KLA .94 .88 .84 .86 1.01 .92 .94
ATP 1.02 .99 .87 .87 1.58 .98 .96
KLA/ATP .94 .82 .83 .77 1.09 .93 1.02